Zerun Biotechnology

Explore the latest insights on Zerun Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Zerun Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Deals

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Co., Ltd. ("Luyan Pharma") signed an exclusive strategic cooperation agreement with Curae LAB, a subsidiary of the French GTH Group, for the Synergia brand in Greater China.…

November 12, 2026

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

November 12, 2026

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

November 12, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

February 11, 2025

Zerun Biotechnology

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

Empowering Chinese Pharma’s Global Expansion

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

About Company